Skip to content

The Effect of Low-Dose Eschlorazepam on the Muscle Relaxant Effect of Transescaline Atropine

The Effect of Low-Dose Eschlorazepam on the Muscle Relaxant Effect of Transescaline Atropine

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500106069
Enrollment
Unknown
Registered
2025-07-16
Start date
2024-08-05
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complete onset of muscle relaxation and complete recovery

Interventions

Esketamine group (ES group):Intravenous injection of 0.25mg/kg esmketamine was administered
Normal saline group (NS group):An equal volume of normal saline was administered intravenously

Sponsors

The Second Affiliated Hospital of Shantou University Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: 1. ASA grading I-II; 2. Age 18-64 years old; 3. Elective surgery, tracheal intubation and general anesthesia, estimated operation time 1-4h; 4.18.5<=BMI<30; 4. Able to understand the trial and voluntarily sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Abnormal intraoperative body temperature (>37.5 or 4h or blood loss> 600ml; 4. Preoperative disorders of water, electrolyte and acid-base balance; 5. Previous trauma or disability of the proposed parts of both hands; 6. Those who are found to have suspected allergic reactions to the study drug or other anesthetic drugs; 7. Women who are pregnant or lactating or have a birth plan for 6 months (including men); 8. Lesions of important organs or organs (heart, brain, liver, kidneys or lungs) before surgery; 9. Untreated or poorly controlled hypertension (>=180/110mmHg) or diabetes mellitus (fasting blood glucose>=8.0) before surgery; 10. Comorbid psychiatric or neuromuscular system diseases; 11. Preoperative use of calcium channel blockers, aminoglycoside antibiotics or phenytoin sodium and other drugs that affect the strength and/or duration of muscle relaxants; 12. Patients who are unwilling to participate in the trial, who have lost their clinical data, and who are judged by other investigators to be unsuitable to participate.

Design outcomes

Primary

MeasureTime frame
Onset time of muscle relaxation;

Secondary

MeasureTime frame
Hemodynamic parameters (heart rate, mean blood pressure);Incidence of adverse reactions;Tracheal intubation condition score;Muscle relaxation recovery index;

Countries

China

Contacts

Public ContactZhang Yongfa

The Second Affiliated Hospital of Shantou University Medical College

259395234@qq.com+86 754 88915661

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026